US FDA Approved Amphastar Pharma’s Nasal Spray to Treat Opioid Overdose

The US Food and Drug Administration (FDA) has approved Amphastar Pharmaceuticals, Inc.’s New Drug Application (NDA) for naloxone hydrochloride nasal spray, 4 milligrams, to treat Opioid Overdose. Naloxone hydrochloride nasal spray 4mg is indicated for the immediate treatment of adult and pediatric patients suffering from respiratory and/or central nervous system depression as a result of […]

Continue Reading

US FDA Approves Shorla Oncology’s Nelarabine Injection to Treat T-Cell Leukemia

Nelarabine Injection, an oncology drug developed by Shorla Oncology, has received US FDA approval for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL). Nelarabine Injection offers patients a substitute for a product that has historically been scarce. Sharon Cunningham, CEO and co-founder of Shorla Oncology, said that they are very […]

Continue Reading

US FDA Approved Alembic Pharma’s Colon Cancer Injection

The US FDA approved Alaembic Pharma’s Fluorouracil Injection USP, 2.5 g/50 mL (50 mg/mL) in India. Patients with colon and rectal adenocarcinomas, breast adenocarcinomas, gastric adenocarcinomas, and pancreatic adenocarcinomas are treated with the injection. Fluorouracil Infusion has an expected market size of $5 million for a considerable length of time finishing December 2022, as indicated […]

Continue Reading

US FDA Approves Moderna’s Skin Cancer Therapy

On, February, 22, 2023, Moderna Inc. said that US regulators have given its experimental personalised mRNA skin cancer vaccine and Merck & Co.’s drug Keytruda the designation of breakthrough therapies as an additional treatment for high-risk patients. After the market closed Moderna shares rose 2.5% to $164. Based on data from a mid-stage drug study […]

Continue Reading